28.11.2013 • NewsbiopharmaceuticalschemicalsGlucophage

Merck KGaA to Build New Pharma Plant in China

German chemicals and pharmaceuticals producer Merck KGaA plans to invest €80 million in a new pharmaceutical plant in the Nantong Economical Technological Development Area of Greater Shanghai. The Darmstadt-based company said production will focus on its leading brands referenced in China's essential drug list and serve the country's expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders.

The new facility, the second largest site worldwide for biopharmaceuticals arm Merck Serono, will concentrate on bulk production and packaging of the drugs Glucophage, Concor and Euthyrox  for treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. Construction is scheduled to begin in 2014, with commercial production to start in 2017. Merck said maximum resource efficiency and minimized waste generation during the manufacturing process will be targeted.

Merck has been present in China for 80 years. Over the past five years, Merck Serono has invested in a research center in Beijing, which focuses on biomarker research, including pharmacogenomics and bioanalytics. The company also maintains what it said is "an extensive network of collaborations" with leading academic and medical institutions, as well as local companies. Earlier in November, it announced a second co-development and commercialization agreement with BeiGene, building on an existing collaboration in oncology.

In Shanghai, Merck Millipore recently opened a biopharmaceutical technical and training center in China and will shortly start up a liquid Crystals manufacturing facility there.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.